California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

Dynavax’s battle with activist investor Deep Track Capital over the biopharma’s direction has heated up again as the ...

The FDA has approved its first at-home collection kit that allows women to screen themselves for human papillomavirus (HPV) ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

The FDA has appointed its first chief artificial intelligence officer, with an eye on supporting the agency’s internal IT ...

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China ...

In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with ...

Vor Bio is the latest cell therapy company to reach the end of the road. | Vor Bio is the latest cell therapy company to ...